


Filling in the Gaps: The role functional genomics can play in 21st century toxicology for environmental risk assessment




NAS Workshop: The Promise of Genome Editing Tools to Advance Environmental Health Research
January 10-11, 2018

Keith Houck
National Center for Computational Toxicology

All Understand Why We Need to Innovate In This Space...

Number of Chemicals/Combinations




Why?

Ethical Concerns




Lack of Data



Modified from Judson *et al.*, EHP 2010


Economics



One Approach: High-Throughput Hazard Screening



ToxCast

Tox21





MIE's/pathways

Models




Promiscuous Chemical Response is the Rule

1000 chemicals/
800 assay endpoints




Thomas et al., 2013

Troglitazone




Assays




Beginning to Address Concerns for Increased Biological Coverage

Gene Coverage




■ ToxCast
■ Not in ToxCast

Pathway Coverage*




*At least one gene from pathway represented


High-throughput Genomics (HTTr)



Thousands of chemicals



Multiple Cell Types



Requirements:

- Low cost
- Whole genome
- 384 well
- Automatable





Connectivity Mapping Demonstrates Multiple Pathway Matches

- Differential gene expression observed with reference chemicals


- Putative targets identified using Connectivity Mapping

- Large degree of promiscuity of predicted targets observed

- Currently evaluating additional methods for MIE prediction




Pathway Potencies by BMD Analysis




- Broad range of pathway level potency estimates and number of pathways affected across chemicals.

Framework for Integrating Hazard Components...



Functional genomics: Defining Relevancy


- Most chemicals have apparent polypharmacology—what is the critical/relevant MOA?
 - Could use potency to define but this may not be linked to adversity
 - Transcriptomics is high content but function is generally inferred
- Functional genomics allows for bridging between genotype and phenotype
- Previously mostly used in prokaryotic systems such as *S. cerevisiae*
- Advent of CRISPR-Cas9 opens door for higher throughput applications in mammalian cells



Gilbert et al., Cell, 2014

Environmental Application of Functional Genomics

- Trichloroethylene (TCE) metabolite study in yeast mutants (n=4607)
- Genome-wide profiling of yeast mutants (n=4607) identified the error-prone translesion synthesis (TLS) pathway conferring sensitivity to TCE metabolite DCVC
- Results were confirmed in a eukaryotic system using DT40 avian kidney cells




De la Rosa et al., Toxicological Sciences, 2017

Pilot Project

- Collaboration between University of Florida (Chris Vulpe) and USEPA (NCCT, Keith Houck)
- Funded by USEPA SMARTi award to Keith Houck and Audrey Bone
- **Goal of the project is to test the feasibility of using CRISPR-Cas9 genome editing in human cells for screening environmental chemicals in a functional genomics toxicology format**

Experimental Design




Chemical Selection

- Criteria

- Mix of uses
(pharmaceutical, pesticide, consumer, industrial)
- Well-characterized mechanisms of cytotoxicity
 - Mitochondrial toxicity
 - DNA damage
 - Oxidative stress
 - Microtubule disruption
 - Proteasome inhibition
- Known cytotoxic in Tox21/ToxCast assays without metabolic activation

- 11 chemicals

- Colchicine
- Triphenyltin chloride
- Triglycidyl isocyanurate
- Cytembena
- Propargite
- Octhilineone
- Triclosan
- Tralopyril
- Dibutyltin dichloride
- Malachite green
- Bisphenol A glycidyl methacrylate



Triclosan

Weaknesses

- Current approach limited to identifying genes that lead to reduction in cell viability
- Problems inherent to CRISPR tech
 - Unintended mutations
- “Pathway” analysis
- Larger perspective- same problems as other HTT approaches
 - Metabolic capacity
 - Toxicokinetic integration
- BUT functional aspects increases confidence in relevance of specific genes to adverse effects

Future Needs for Pathway to Integration of Functional Genomics into Environmental Risk Assessment

- More proof-of-concept and pilot studies with well-characterized chemicals
- Development of assay technology that facilitates expansion of functional endpoints beyond cell viability
 - in vivo* assays in organisms suited to HTT such as *C. elegans* or *Danio rerio*
 - cell line engineering of pathway reporter lethality assays*
- Dependent on continued integration of HTT into risk assessment paradigms

- Validation of HTTr signatures
- Validation of AOPs
 - What is the effect of knockdown/activation of MIE's/KE's to the adverse endpoint?
 - Can this help with the development of **quantitative** AOP's?
- Rapid generation of specific animal model MOAs
 - Sensitivity/resistance to specific MOA's
 - Modulation of critical ADME parameters
- Generation of sensitive population models *in vivo* and *in vitro*
 - Single genetic mutation disease models
 - Engineered ADME genetic variability
 - SNP recapitulation of sensitive populations from GWAS-type studies (complex)
 - Validation of sensitivities identified through GWAS-type analysis

Thank You for Your Attention!

Acknowledgements

EPA Colleagues:

NCCT

Audrey Bone (*Bayer*)

Joshua Harrill

Imran Shah

Rusty Thomas

NCEA

Tina Bahadori

Jeff Dean

Jason Lambert

NIEHS

Allison Harrill

Univ. of Florida

Chris Vulpe

Abderrahmane Tagmount



EPA's National Center for Computational Toxicology